Circulation, Vol 87, 1850-1853, Copyright © 1993 by American Heart Association
D Collen and F Van de Werf
BACKGROUND. Staphylokinase (STA), a protein with known profibrinolytic
properties, is produced by transduced Staphylococcus aureus strains. In
experimental animal models, recombinant staphylokinase (STAR) is less
immunogenic and more active toward platelet-rich arterial blood clots than
streptokinase. METHODS AND RESULTS. In the present study, 10 mg STAR given
intravenously over 30 minutes was found to induce angiographically
documented coronary artery recanalization within 40 minutes in four of five
patients with acute myocardial infarction. Plasma fibrinogen and alpha
2-antiplasmin levels were unaffected, and allergic reactions were not
observed. Postinfusion disappearance of STAR antigen followed a biphasic
mode with a t1/2 alpha of 6.3 +/- 0.6 minutes (mean +/- SD) and a t1/2 beta
of 37 +/- 15 minutes, corresponding to a plasma clearance of 270 +/- 100
mL/min. Neutralizing antibodies against STAR could not be demonstrated at
baseline and up to 6 days after infusion, but STAR neutralizing activity,
which did not cross-react with streptokinase, was consistently demonstrable
in plasma at 14-35 days. CONCLUSIONS. STAR can induce clot-selective
coronary thrombolysis in patients with evolving myocardial infarction
without concomitant induction of a systemic lytic state. STAR, a small
protein that can be easily produced by recombinant DNA technology, may
therefore offer promise for thrombolytic therapy in patients with
thromboembolic disease.
ARTICLES
Coronary thrombolysis with recombinant staphylokinase in patients with evolving myocardial infarction
Center for Thrombosis and Vascular Research, University of Leuven, Belgium.
This article has been cited by other articles:
 |
|
 |
|
  Q. Lian, S. J. Szarka, K. K. S. Ng, and S.-L. Wong Engineering of a Staphylokinase-based Fibrinolytic Agent with Antithrombotic Activity and Targeting Capability toward Thrombin-rich Fibrin and Plasma Clots J. Biol. Chem., July 11, 2003; 278(29): 26677 - 26686. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Qiujun Lu, Yuanmin Li, Liqing Wen, Shaoming Guo, Yuanyuan Chen, Weijing Liu, Yue Gao, and Lingmao Ding Safety Evaluation of Recombinant Staphylokinase in Rhesus Monkeys Toxicol Pathol, January 1, 2003; 31(1): 14 - 21. [Abstract] [PDF]
|
|
|
|
 |
|
 C. Icke, B. Schlott, O. Ohlenschlager, M. Hartmann, K.-H. Guhrs, and E. Glusa Fusion Proteins with Anticoagulant and Fibrinolytic Properties: Functional Studies and Structural Considerations Mol. Pharmacol., August 1, 2002; 62(2): 203 - 209. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. A. M. Warmerdam, K. Vanderlick, P. Vandervoort, H. De Smedt, S. Plaisance, M. De Maeyer, and D. Collen Staphylokinase-Specific Cell-Mediated Immunity in Humans J. Immunol., January 1, 2002; 168(1): 155 - 161. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A H Gershlick The acute management of myocardial infarction Br. Med. Bull., October 1, 2001; 59(1): 89 - 112. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. W. Armstrong and D. Collen Fibrinolysis for Acute Myocardial Infarction : Current Status and New Horizons for Pharmacological Reperfusion, Part 1 Circulation, June 12, 2001; 103(23): 2862 - 2866. [Full Text] [PDF]
|
|
|
|
|
|
L. Moons, I. Vanlinthout, I. Roelants, R. Moreadith, D. Collen, and H. J. Rapold Toxicology Studies with Recombinant Staphylokinase and with SY 161-P5, a Polyethylene Glycol-Derivatized Cysteine-Substitution Mutant Toxicol Pathol, April 1, 2001; 29(3): 285 - 291. [Abstract] [PDF]
|
|
|
|
 |
|
 A. F. Maes, F. Van de Werf, L. V. Mesotten, P. B. Flamen, R. S. Kuzo, J. L. Nuyts, and L. Mortelmans Early assessment of regional myocardial blood flow and metabolism in thrombolysis in myocardial infarction flow grade 3 reperfused myocardial infarction using carbon-11-acetate J. Am. Coll. Cardiol., January 1, 2001; 37(1): 30 - 36. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. M. Ohman, R. A. Harrington, C. P. Cannon, G. Agnelli, J. A. Cairns, and J.W. Kennedy Intravenous Thrombolysis in Acute Myocardial Infarction Chest, January 1, 2001; 119 (2009): 253S - 277S. [Full Text] [PDF]
|
|
|
|
|
|
D. Collen, P. Sinnaeve, E. Demarsin, H. Moreau, M. De Maeyer, L. Jespers, Y. Laroche, and F. Van de Werf Polyethylene Glycol-Derivatized Cysteine-Substitution Variants of Recombinant Staphylokinase for Single-Bolus Treatment of Acute Myocardial Infarction Circulation, October 10, 2000; 102(15): 1766 - 1772. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. J. Lee, D. M. Kim, K. H. Bae, S. M. Byun, and J. H. Chung Enhancement of Secretion and Extracellular Stability of Staphylokinase in Bacillus subtilis by wprA Gene Disruption Appl. Envir. Microbiol., February 1, 2000; 66(2): 476 - 480. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Vanwetswinkel, S. Plaisance, Z. Zhi-yong, I. Vanlinthout, K. Brepoels, I. Lasters, D. Collen, and L. Jespers Pharmacokinetic and thrombolytic properties of cysteine-linked polyethylene glycol derivatives of staphylokinase Blood, February 1, 2000; 95(3): 936 - 942. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 O. Iqbal, H. Messmore, D. Hoppensteadt, J. Fareed, and W. Wehrmacher State-of-the-Art Review : Thrombolytic Drugs in Acute Myocardial Infarction Clinical and Applied Thrombosis/Hemostasis, January 1, 2000; 6(1): 1 - 13. [PDF]
|
|
|
|
|
|
N. Nagai, I. Vanlinthout, and D. Collen Comparative Effects of Tissue Plasminogen Activator, Streptokinase, and Staphylokinase on Cerebral Ischemic Infarction and Pulmonary Clot Lysis in Hamster Models Circulation, December 21, 1999; 100(25): 2541 - 2546. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F.J. Van de Werf The ideal fibrinolytic: can drug design improve clinical results? Eur. Heart J., October 2, 1999; 20(20): 1452 - 1458. [PDF]
|
|
|
|
|
|
R. G. Miele, M. Prorok, V. A. Costa, and F. J. Castellino Glycosylation of Asparagine-28 of Recombinant Staphylokinase with High-Mannose-type Oligosaccharides Results in a Protein with Highly Attenuated Plasminogen Activator Activity J. Biol. Chem., March 19, 1999; 274(12): 7769 - 7776. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Jenne, K. Brepoels, D. Collen, and L. Jespers High Resolution Mapping of the B Cell Epitopes of Staphylokinase in Humans Using Negative Selection of a Phage-Displayed Antigen Library J. Immunol., September 15, 1998; 161(6): 3161 - 3168. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A H Gershlick and R S More Recent advances: Treatment of myocardial infarction BMJ, January 24, 1998; 316(7127): 280 - 284. [Full Text]
|
|
|
|
|
|
D. Collen, F. De Cock, E. Demarsin, S. Jenne, I. Lasters, Y. Laroche, P. Warmerdam, and L. Jespers Recombinant Staphylokinase Variants With Altered Immunoreactivity: III: Species Variability of Antibody Binding Patterns Circulation, January 21, 1997; 95(2): 455 - 462. [Abstract] [Full Text]
|
|
|
|
|
|
D. Collen, R. Bernaerts, P. Declerck, F. De Cock, E. Demarsin, S. Jenne, Y. Laroche, H. R. Lijnen, K. Silence, and M. Verstreken Recombinant Staphylokinase Variants With Altered Immunoreactivity: I: Construction and Characterization Circulation, July 15, 1996; 94(2): 197 - 206. [Abstract] [Full Text]
|
|
|
|
|
|
D. Collen, H. Moreau, L. Stockx, and S. Vanderschueren Recombinant Staphylokinase Variants With Altered Immunoreactivity: II: Thrombolytic Properties and Antibody Induction Circulation, July 15, 1996; 94(2): 207 - 216. [Abstract] [Full Text]
|
|
|
|
|
|
D. Collen Fibrin-Selective Thrombolytic Therapy for Acute Myocardial Infarction Circulation, March 1, 1996; 93(5): 857 - 865. [Full Text]
|
|
|
|
|
|
K.-L. Neuhaus More on Thrombolysis and Hemorrhagic Stroke Circulation, November 15, 1995; 92(10): 2794 - 2795. [Full Text]
|
|
|
|
|
|
K. Silence, M. Hartmann, K.-H. Gührs, A. Gase, B. Schlott, Dés. Collen, and , H. R. Lijnen Structure-Function Relationships in Staphylokinase as Revealed by ``Clustered Charge to Alanine'' Mutagenesis J. Biol. Chem., November 10, 1995; 270(45): 27192 - 27198. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Vanderschueren, L. Barrios, P. Kerdsinchai, P. Van den Heuvel, L. Hermans, M. Vrolix, F. De Man, E. Benit, L. Muyldermans, D. Collen, et al. A Randomized Trial of Recombinant Staphylokinase Versus Alteplase for Coronary Artery Patency in Acute Myocardial Infarction Circulation, October 15, 1995; 92(8): 2044 - 2049. [Abstract] [Full Text]
|
|
|
|
|
|
S. Vanderschueren, L. Stockx, G. Wilms, H. Lacroix, R. Verhaeghe, J. Vermylen, and D. Collen Thrombolytic Therapy of Peripheral Arterial Occlusion With Recombinant Staphylokinase Circulation, October 15, 1995; 92(8): 2050 - 2057. [Abstract] [Full Text]
|
|
|
|
|
|
A. Maes, F. Van de Werf, J. Nuyts, G. Bormans, W. Desmet, and L. Mortelmans Impaired Myocardial Tissue Perfusion Early After Successful Thrombolysis : Impact on Myocardial Flow, Metabolism, and Function at Late Follow-up Circulation, October 15, 1995; 92(8): 2072 - 2078. [Abstract] [Full Text]
|
|
|
|
|
|
J. M. Stassen, A. Nystrom, M. Hoylaerts, and D. Collen Antithrombotic Effects of Thrombolytic Agents in a Platelet-Rich Femoral Vein Thrombosis Model in the Hamster Circulation, March 1, 1995; 91(5): 1330 - 1335. [Abstract] [Full Text]
|
|